Background: Antibiotics are inappropriately prescribed to many people with sore throat. As most cases of sore throat are viral and/or self-limiting, guidelines recommend symptomatic management as first-line treatment. This paper reviews the available clinical evidence for the efficacy and safety of low-dose (8.75 mg) flurbiprofen, locally delivered to the throat for the symptomatic management of pharyngitis/sore throat. Method: A literature search was performed on 27 February 2019 using PubMed. Studies that met the following criteria were included in a narrative review: (1) studies evaluating the effectiveness of flurbiprofen for pharyngitis/sore throat; (2) randomized controlled studies; (3) locally administered formulation of study drug/comparator; and (4) flurbiprofen administered at 8.75 mg dose (single-or multiple-dose administration). Results: A total of 17 papers were included in the review: 15 publications reporting data from nine unique clinical studies of flurbiprofen for acute pharyngitis, and two reporting studies of flurbiprofen for the prevention of postoperative sore throat (POST). Studies in acute pharyngitis demonstrated that single-and multiple-dose flurbiprofen 8.75 mg, locally administered in lozenge, spray or microgranule form, was well tolerated and provided early onset and long-lasting symptomatic relief from throat pain and soreness, sensation of swollen throat, difficulty swallowing, and other associated symptoms. This included patients with more severe symptoms, patients with confirmed Streptococcus A/C sore throat, and patients taking concomitant antibiotics. In addition, a single preoperative dose of flurbiprofen lozenge was shown to be effective for relieving early POST in patients undergoing general anesthesia. Conclusion: Locally administered, low-dose flurbiprofen offers a useful first-line treatment option for symptomatic relief in patients with "uncomplicated" acute pharyngitis/sore throat associated with upper respiratory tract infection, thus potentially helping to reduce unnecessary antibiotic prescribing. It also offers an effective preoperative treatment option for the reduction of early POST severity and incidence.
Introduction
Pharyngitis is one of the most common reasons patients seek advice from a healthcare provider (HCP) in primary care. 1 Although not life-threatening, pharyngitis, particularly symptoms such as sore throat, can have a substantial negative impact on an individual's daily life. 2 Relief from the severe symptoms of pharyngitis are a key driver of patients' consultations with HCPs, and of antibiotic-seeking behavior, 3, 4 with complaints of sore throat constituting between 1% and 4% of all primary care presentations internationally. 5, 6 Pharyngitis is generally of infectious etiology, with the vast majority of cases caused by self-limiting viral infections. 7 Only around 5-30% of cases are attributed to bacterial etiologies -with approximately 10% to group A β-hemolytic Streptococcus pyogenes (strep A) [7] [8] [9] [10] -although other bacteria, including
Streptococcus dysgalactiae (strep C), have been implicated. 9 Pharyngitis symptoms typically last 3-7 days, 11 but are often worst during the first few days. 12, 13 The natural course of pharyngitis is similar in most patients, regardless of whether they are strep positive or not. 14 Guidelines recommend symptomatic management of pharyngitis as a first-line treatment, and suggest avoiding or delaying antibiotic use in acute pharyngitis, except in the minority of patients with more severe strep infection or risk factors for serious complications such as rheumatic fever. 15, 16 The availability of rapid and effective symptomatic relief is, therefore, an important factor in meeting patients' expectations and avoiding unnecessary use of antibiotics; 3 most cases of pharyngitis can be managed by patients using over-thecounter (OTC) treatments as a means of controlling their symptoms. 15, 16 As inflammation is the underlying cause of pharyngitis, 12 treatment of the condition with a nonsteroidal anti-inflammatory drug (NSAID) can offer rapid and longlasting relief from pain. 17, 18 To minimize the potential risk of an adverse event, regulatory bodies and medical societies recommend using the lowest effective NSAID dose for the shortest time necessary to control symptoms. 19 Locally administered formulations of NSAIDs, such as lozenges and sprays, facilitate targeted application of active ingredient to the throat, 20 allowing absorption of the drug directly where it is needed. 21 This allows administration of a lower dose than systemic therapy, 22 reducing the potential for adverse effects. 23, 24 Flurbiprofen is an NSAID that has been formulated for local delivery at a low dose and is commercially available as a single active ingredient in both lozenge and spray formulations. 25, 26 It is most commonly used at a dose of 8.75 mg, based on the results of a dose-ranging study that demonstrated linear dose-response relationships for effectiveness and adverse events at doses between 5.0 mg and 12.5 mg. 27 Its use for the symptomatic relief of pharyngitis of viral, bacterial, or unknown etiology has been assessed in a number of studies. 17, 22, 25, 26, [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] It has also been evaluated for the relief of postoperative sore throat POST, [39] [40] [41] a common complication of general anesthesia 42 and tonsillectomy 43 that can negatively impact patients' postoperative comfort.
The aim of this paper is to review the available clinical evidence for the efficacy and safety of low-dose (8.75 mg) flurbiprofen, locally delivered to the throat for the symptomatic management of pharyngitis/sore throat. This review predominantly focuses on the management of sore throat associated with upper respiratory tract infection (URTI); its use for POST prevention is discussed in brief.
Methods

Search Strategy
A literature search was performed on 27 February 2019 using PubMed (including MEDLINE), with a search string including the following: "flurbiprofen" The full text of all potentially relevant publications was then reviewed to confirm inclusion and to determine whether a meta-analysis of the data was feasible. If a meta-analysis was not deemed possible, a narrative review of the evidence would be performed.
Results
The PubMed search identified 33 unique records, of which 15 were excluded as they did not meet the inclusion criteria based on title/abstract screening ( Figure 1 ). A total of 18 records underwent full text assessment: 17 were selected for inclusion in the final review (Table 1) , and one study in POST was excluded as it evaluated a flurbiprofen dose lower than 8.75 mg. 39 In view of the heterogeneity of the data reported in the studies identified, it was not possible to conduct a metaanalysis. For example, studies varied with regard to the formulation by which the active ingredient was administered (lozenge, spray, and microgranules), the outcome measures investigated, the nature of data reported (some studies reported baseline and endpoint data, whereas others only reported efficacy in terms of percentage change from baseline) and the data reporting units. A narrative review was therefore determined to be the appropriate methodology.
Acute Pharyngitis
Fifteen publications, reporting data from nine unique clinical studies of flurbiprofen for acute pharyngitis, were included in this review (Table 1) . Ten publications reported data for flurbiprofen lozenges vs placebo, two reported data for flurbiprofen spray vs placebo, two compared flurbiprofen lozenges and spray, and one reported data for flurbiprofen microgranules vs placebo. All flurbiprofen study medications were provided by Reckitt Benckiser. All studies included adult patients with confirmed pharyngitis due to URTI, with the exception of one study including patients aged 12 years and over which did not specifically screen for URTI. 31 Patients were eligible for inclusion if they reported acute onset of pharyngitis (range: 3-7 days or less) and moderate to severe symptoms. The effectiveness of flurbiprofen has been assessed using several different outcome measures; Table 2 provides descriptions of the key endpoint measures and tools used in the included studies.
Throat Pain and Soreness
Overall, flurbiprofen 8.75 mg generally provided significant relief of sore throat pain and soreness compared with placebo (Table 3) , as measured on the Sore Throat Pain Intensity Scale (STPIS), Sore Throat Relief Rating Scale (STRRS), Throat Soreness Scale (TSS) and Sore Throat Scale (STS) ( Table 2 ).
Single Dose
Fourteen papers reported data on the effectiveness of singledose flurbiprofen 8.75 mg for relieving throat pain and soreness; 17, 22, 25, 26, [28] [29] [30] [31] [32] [33] [34] [35] 37, 38 11 included data for flurbiprofen lozenges, four for flurbiprofen spray and one for flurbiprofen microgranules. In a study by Schachtel et al, 17 single-dose flurbiprofen lozenge demonstrated a significantly greater reduction (85%) in sore throat pain intensity summed over the 2 h post-dose period (as measured on the STPIS) compared with placebo (p<0.001). Moreover, in another study by Schachtel et al, 35 almost all (97%) patients treated with a single flurbiprofen lozenge experienced a reduction in sore throat pain intensity over the 3 h postdose period (vs 76% of placebo-treated patients; p<0.01). Several other papers also reported significantly greater reductions in sore throat pain intensity compared with placebo with single-dose flurbiprofen lozenge, 29, 30, 37 spray, 34 and microgranules 38 for up to 3-6 h post-dose (specific percentage reductions were not provided). Regarding absolute/percentage reductions in sore throat pain intensity/soreness from baseline, significantly greater reductions were observed with flurbiprofen vs placebo at all individual timepoints up to 2-4 h in several studies. 17, 22, [29] [30] [31] [32] [33] [34] [35] 37 Radkova et al 26 observed an STPIS pain intensity difference from baseline to 2 h post-dose of −40.51 and −40.10 with flurbiprofen spray and lozenges, respectively. No significant difference was observed between single-dose flurbiprofen spray and lozenge in terms of improvement in sore throat pain intensity. 25, 26 Figure 1 Publication assessment process. that 74-78% of patients experienced "at least moderate relief" by 2 h post-dose with flurbiprofen lozenge or spray, and 98% experienced "slight" relief over the same period. In the study by Schachtel et al, 17 the sum of total pain relief scores (TOTPAR), calculated from the STRRS, was 82% greater with flurbiprofen lozenge compared with placebo over the 1-2 h post-dose period (p<0.001), with 53% of patients taking flurbiprofen experiencing "at least moderate relief" (compared with 26% of placebo patients; p<0.001). Several other studies have also reported significantly greater improvements in sore throat relief with single-dose flurbiprofen (lozenges, spray or microgranules) vs placebo for between 2 and 6 hrs post-dose. 32, 34, 38 Radkova et al 26 and Burova et al 25 reported similar efficacy of single-dose flurbiprofen spray and lozenge for sore throat relief. One paper, by Watson et al, 22 failed to demonstrate a significant improvement in TOTPAR over 2 h vs placebo, although a trend in favor of flurbiprofen lozenge was observed (p=0.06). However, analysis of sore throat relief at individual time points revealed significant differences in favor of flurbiprofen compared with placebo at 45, 60, and 75 min (p<0.05). Significant reductions in throat soreness (as measured on the TSS and STS) have also been observed with singledose flurbiprofen across all studies reporting these measures, ranging from 23% to 124% greater reductions in throat soreness vs placebo over 2 h, where numerical data are reported. 22, 28, 31, 32, 34, 38 Multiple Dose Eight of the papers have provided clinical evidence that multiple-dose flurbiprofen, taken every 3-6 h as needed (up to 5 or 8 doses in 24 h), provide continued relief from sore throat pain and soreness; 22, [29] [30] [31] 34, [36] [37] [38] six for flurbiprofen lozenges, one for spray, and one for microgranules. Several of the papers evaluated pain relief during the first 24 h of treatment, when throat symptoms are most prominent and often require repeated treatment. 29, 30, 36, 37 All of these papers reported significant reductions in sore throat pain (up to 80% greater compared to placebo; measured on the STPIS) over this treatment period. 29, 30, 36, 37 Five papers explored the efficacy of repeated self-dosing of flurbiprofen beyond the first 24 h. Schachtel et al 36 observed that multiple-dose flurbiprofen lozenge over days 2-7 continued to provide significant reductions in sore throat pain intensity from before to 2 h after each dose, and that flurbiprofen provided 74% greater reduction in sore throat pain intensity vs placebo over days 2-7 (p<0.01). Likewise, de Looze et al 34 reported that multiple-dose flurbiprofen spray provided a greater reduction in severity of throat soreness and pain intensity, and significantly greater sore throat relief compared with placebo, up to the end of the 3-day study period (p<0.05). Blagden et al 31 demonstrated the superiority of flurbiprofen vs placebo in relieving sore throat over days 1-4 overall (TOTPAR at the end of days 1-4; p=0.0113). However, in a subgroup of patients not prescribed concomitant antibiotics in this study, significance was reached on days 2 and 3 (p<0.05), but not on day 1 (p=0.06) and day 4 (p=0.09). In terms of change from baseline in sore throat relief, significance was achieved with multiple-dose flurbiprofen microgranules vs placebo at the end of day 1 (p=0.026), but not at the end of day 2 (p=0.101) and day 3 (p=0.078).
38
Severe Sore Throat In a study by Aspley et al, 29 the efficacy of flurbiprofen lozenge was evaluated in a subgroup of patients with relatively severe sore throat pain (baseline STPIS score of >80.5 mm). In these patients, multiple-dose flurbiprofen provided 135.7% greater (269.9 mm*h; 95% CI: 84.7, 455.1) reduction in pain intensity than placebo-treated patients (p<0.01) over 24 h. Improvement of sore throat pain after single-dose flurbiprofen was similar for patients with relatively severe symptoms and the overall study population, with onset differentiated between flurbiprofen and placebo beginning at approximately 30-40 min through to 3 h (p<0.05). Moreover, Schachtel et al 35 reported that pain reduction was achieved by 95% of flurbiprofen-treated patients over 3 h (vs 63% of placebo-treated patients; p=0.02) in a subgroup of patients (42%) with more severe • Placebo (n=100):
Difference from pre-dose to 2 h post-dose in STPIS (LS mean scores) over days 2-7 (mm)
• Flurbiprofen (n=94):
• Placebo (n=96):
Multiple dose Abbreviations: AUC, area under the change from baseline curve; LS, least square; NA, not applicable; NR, full data not reported; NS, not significant; SPID, Summed Pain Intensity Difference; STPIS, Sore Throat Pain Intensity Scale; STRRS, Sore Throat Relief Rating Scale; STS, Sore Throat Scale; TOTPAR, sum of total pain relief scores; TSS, Throat Soreness Scale. sore throat pain at baseline (STS score >7 and TonsilloPharyngitis Assessment [TPA] score >7).
Meaningful Pain Relief
Determining a reduction in pain that is clinically important, or meaningful to patients, may offer more interpretable results with direct clinical implications. 44 Several of the studies included in this review have assessed "meaningful" pain relief with flurbiprofen. 17, 18, 33, 35 Using a double stopwatch (DSW) method (Table 2) , Schachtel et al 35 investigated both "first perceived" pain relief (the moment the patient experiences any pain relief, measured on the STPIS) and "meaningful" pain relief (when the patient experiences relief that is meaningful to them) with flurbiprofen lozenge. Results showed that 97% of flurbiprofentreated patients (n=101) experienced "first perceived" pain relief, with 78% achieving "meaningful" analgesia within the 3 h study period. In contrast, although 76% of patients taking placebo lozenge (n=21) reported "first perceived" pain relief over the 3 h study period, the relief was not considered "meaningful" in over half of patients (52%). "Meaningful" pain relief was achieved by 32% (32/101) of flurbiprofen-treated patients within 30 min and by 66% (67/101) within 60 min -compared with 19% (4/21) and 43% (9/21) of placebo-treated patients, respectively. A subgroup analysis also demonstrated significant efficacy of flurbiprofen in patients with more severe sore throat; in these patients, "meaningful" relief was reported by 70% of flurbiprofen-treated patients and 13% of placebo-treated patients (p<0.01). Meaningful pain relief was also assessed by Schachtel et al 17 in another study using the established criteria of "at least moderate relief" of acute pain to define a clinically important effect size. Sore throat pain was assessed at frequent (2 min) intervals on the STPIS, and onset of pharmacological activity was defined as the median time of "first perceived" pain reduction if a patient reported clinically meaningful "at least moderate" relief. Patients receiving a single flurbiprofen lozenge first reported "meaningful" pain relief at 12 min, with a significant differentiation from placebo in terms of percentage reduction in pain intensity (indicative of change relative to each individual patient's pretreatment pain intensity) beginning at 26 min (24% pain reduction with flurbiprofen vs 16% with placebo; p<0.05).
The previous findings were confirmed with flurbiprofen spray in a study by de Looze et al. 33 Patients were required to report at least 30 min of "at least moderate" sore throat relief on the STRRS for the relief to be regarded as "clinically meaningful". Significantly more patients using flurbiprofen spray reported at least 30 min of "at least moderate" relief than those using placebo during the 6 h after a single dose (55% vs 35%, respectively; OR: 2.31; 95% CI: 1.61, 3.62; p<0.0001), and this was achieved more quickly with flurbiprofen than placebo (HR: 1.96; 95% CI: 1.50, 2.57; p<0.0001); 150 min for flurbiprofen and not calculated for placebo due to less than 50% response. Sore throat severity was reduced by at least 2.2 mm on the STS from 75 min to 6 h post dosing, indicating "meaningful relief".
Difficulty Swallowing
Eleven of the papers reviewed reported data evaluating the efficacy of flurbiprofen in reducing difficulty swallowing (Table 4 ) -a common symptom associated with inflammation of the throat, usually measured on the Difficulty Swallowing Scale (DSS; Table 2 ). Significantly greater improvements in swallowing have been observed from 5 min after taking single-dose flurbiprofen compared with placebo, 34 and for up to 6 h post-dose. 34 The 
Sensation of Swollen Throat
Eleven of the papers reported data evaluating the efficacy of flurbiprofen in reducing the sensation of swollen throat (Table 5) , commonly assessed on the Swollen Throat Scale (SwoTS; Table 2 ). As with the other symptoms associated with sore throat, the data generally support that flurbiprofen is effective at reducing the sensation of swollen throat rapidly after a single dose -with significantly greater reductions observed from 30 min to up to 6 h post-dose 17,25,30,32,34,37 -and after multiple dosing over 1-7 days. 22, 29, 30, 34, 36, 37 Notably, Aspley et al 29 observed a 69.3% greater reduction in sensation of swollen throat with multiple-dose flurbiprofen lozenges compared with placebo over 24 h (p<0.05), and an even greater reduction (148.6%) in patients who had relatively severe symptoms (baseline SwoTS score >81.5 mm). Combined data from NCT01048866 and NCT01049334.
Abbreviations: AUC, area under the curve; DSS, Difficulty Swallowing Scale; LS, least squares; NR, full data not reported; QuaSTI, Qualities of Sore Throat Index. Combined data from NCT01048866 and NCT01049334.
Abbreviations: AUC, area under the curve; DSS, Difficulty Swallowing Scale; LS, least squares; NR, not reported; QuaSTI, Qualities of Sore Throat Index; SwoTS, Swollen Throat Scale.
Only one study reported no difference between single-dose flurbiprofen and placebo in reduction of sensation of swollen throat over 2 and 6 h, but did report significant reductions in the symptom on days 3 (p=0.005) and 4 (p=0.001) of multiple dosing. 22 
Onset of Action
Several studies indicated that locally administered flurbiprofen can provide symptomatic relief from sore throat and associated symptoms from 1-30 min after taking a single dose, depending on the first assessment time point (Table 6) . 17 formulations of flurbiprofen, and at 10 min post-dose (the first assessment time point) with lozenges (all p<0.05). 29 A significantly greater reduction in sensation of swollen throat was also achieved at 30 min post-dose vs placebo with lozenges (p<0.05) 32 and with flurbiprofen spray (p<0.001). 34 Onset of analgesia attributable to the active ingredient of a lozenge is complicated by the inherent demulcent effect of the sugary vehicle base of the lozenge itself, which provides an immediate, but short-lived, soothing effect as a result of increasing salivation and lubrication of the mucosa. 24, 44 Assessments at 2-min intervals during the early stages of studies have demonstrated this effect. 17, 29 Several of the reviewed studies specifically assessed the onset of clinically relevant, or "meaningful", analgesia with flurbiprofen in order to distinguish the analgesic effect of flurbiprofen from the demulcent effect of the lozenge base. 17, 33, 35, 38 As mentioned previously in the "Meaningful Pain Relief" section, median onset of pharmacological activity ("time to the first perceived reduction of sore throat pain" confirmed by "at least moderate pain relief") was 12 min in patients taking flurbiprofen lozenge, compared with over 120 min (last assessment time) for the placebo group (p<0.001) in the study by Schachtel et al. 17 In another paper from Schachtel et al, 35 using the previously described DSW method, median time to "first perceived pain relief" for flurbiprofen-treated patients was 11 min (95% CI 
Duration of Action
Data from several studies suggest that single-dose flurbiprofen can provide long-lasting symptomatic relief of sore throat and associated symptoms over several hours (Table 6) . 17 swollen throat, and significantly improved sore throat relief vs placebo for at least 2-4 h, dependent on the study assessment period. 17, 22, 29, 30, 32, 35, 37 Other Symptoms Associated with Sore Throat
Qualities of Sore Throat Index (QuaSTI) Patients with pharyngitis commonly report a number of symptoms beyond just "sore throat" when they seek professional intervention, and these symptoms may be described using a wide variety of sensory, emotional, and functional terms. 28 Two papers 25, 28 have assessed the ability of flurbiprofen to provide relief from 10 features of sore throat commonly reported by patients using the recently developed and validated QuaSTI ( Table 2) . Schachtel et al 28 demonstrated a significant improvement (ie reduction in mean overall QuaSTI score) from baseline to 3 h post-dose with single-dose flurbiprofen lozenge (mean ±SD, −19.3 ± 18.62; p<0.001). This improvement was significantly greater with flurbiprofen compared with placebo lozenge (154%; p<0.05). With regards to the individual qualities of sore throat, patients using flurbiprofen lozenge consistently reported significant reductions of scores from baseline at 1, 2, and 3 h (all p<0.01). In addition, the changes in QuaSTI were confirmed as "clinically significant" for some of the individual qualities, with differences from pretreatment levels of at least two points on the Likert scales for swollen throat, difficulty swallowing, agonizing and throat soreness. There was a reduction from baseline to 2 h of at least two points for all the individual symptoms of sore throat on the QuaSTI, signifying "clinically significant" changes.
URTI Symptoms
Sore throat associated with acute URTI is often accompanied by other troublesome upper respiratory tract symptoms, for example cough, post-nasal drip, swollen or tender neck glands, tickly throat, achiness and lack of energy. 25, 28 These can be assessed using the URTI questionnaire (Table 2 ). Schachtel et al 28 observed that significant numbers of patients treated with flurbiprofen lozenges, but not placebo, reported an absence of several URTI symptoms (achiness, pressure around the eyes, mouth breathing, lack of energy, tender neck glands, headache, loss of appetite, sinus pressure, coughing, chest tightness, or sinus pain) at 3 h post-dose compared to pretreatment (all p<0.05). In particular, among patients reporting cough at baseline, 46% (11/24 patients) reported no coughing at 3 h (p=0.01).
Burova et al 25 also demonstrated a significant reduction in the number of patients experiencing URTI symptoms with both flurbiprofen spray and lozenges. At 2 h postdose, the number of patients experiencing URTI symptoms that can be attributed to or associated with sore throat (coughing, post-nasal drip, swollen neck glands, tender neck glands, throat tickle, and throat clearing) decreased relative to baseline. These decreases were statistically significant for every symptom, except tender neck glands (lozenge only; p=0.0881) and throat tickle (both formulations; p=0.3113 for spray and p=0.2249 for lozenge).
There was an 85% and 54% reduction in the number of patients with cough from baseline to 2 h with spray and lozenge, respectively.
Streptococcal versus Non-Streptococcal Pharyngitis
The effectiveness of flurbiprofen in patients with or without strep A/C sore throat has been assessed in several of the reviewed papers. 26, 28, 35, 37 In a paper by Shephard et al, 37 subgroup data from two clinical trials were combined to evaluate the efficacy of flurbiprofen lozenges in patients with and without microbiologically proven strep A/C. Strep A/C was confirmed in 24% (96/401) of patients who had a throat culture test. Significant pain reduction (on the STPIS) with single-dose flurbiprofen compared with placebo was observed for up to 4 h (p<0.01) for the overall population and for patients without strep A/C, and for up to 3 h for patients with strep A/C (both p<0.05). There were no differences in treatment effects in the strep A/C group compared with the non-strep A/C group (p>0.2 for all time points assessed up to 6 h). Likewise, there were no significant differences in flurbiprofen single-dose treatment effects in the strep A/C group compared with the non-strep A/C group for either difficulty swallowing or swollen throat (p>0.05 for all time points assessed up to 6 h). With multiple-dose flurbiprofen, reductions in pain intensity, and improvements in difficulty swallowing and swollen throat, were also similar regardless of strep A/C status, although the improvements observed in the strep A/C group were not statistically different from placebo, possibly due to the small patient numbers or the natural improvement of throat symptoms over time.
In a study by Schachtel et al, strep A/C was detected in 34% (42/122) of patients, and efficacy of flurbiprofen lozenges in reducing sore throat symptoms (on the QuaSTI) was similar regardless of strep A/C status. 28 In a further analysis of the data, 35 among flurbiprofen-treated patients with strep A/C, 82% reported "meaningful" pain relief (on the STPIS) within 3 h compared with 78% in the non-strep group. Moreover, there was no significant difference in median time to "meaningful" relief for flurbiprofen-treated patients with or without strep A/C (41 min vs 43 min, respectively; p=0.39). All patients with strep A/ C reported "first perceived pain relief" with flurbiprofen within the 3-h study period. Likewise, in a study from Radkova et al, 26 although only 5.4% (22/411) of patients tested positive for strep A/C sore throat, subgroup analyses showed similar efficacy (change in pain intensity on the STPIS at 2 h) with flurbiprofen spray and lozenges regardless of strep A/C status.
Concomitant Antibiotic Use
In a study from Blagden et al, 31 59% (135/230) of flurbiprofen lozenge-treated patients also took concomitant antibiotics, as did 58% (133/229) of placebo-treated patients. Antibiotic usage did not affect sore throat relief (reported as TOTPAR) over days 1-4 within the flurbiprofen treatment group.
Patient Satisfaction/Overall Treatment Rating
In addition to assessing the efficacy of flurbiprofen in managing the symptoms of sore throat, several of the studies also evaluated patients' opinions of the overall success of the treatment, most using the Global Evaluation Scale (GLOBAL), the Satisfaction Scale (SATIS) and/or an overall treatment rating scale (Table 2) . 22, 25, 26, [30] [31] [32] 34, 36, 38 Significantly more patients taking flurbiprofen rated their treatment as "good", "very good" or "excellent" on the GLOBAL compared with placebo after single-and multiple-dose treatment. 34, 36 Similarly, there was greater patient satisfaction on the SATIS after treatment, with a significantly higher proportion of patients reporting that they were "satisfied", "very satisfied" or "extremely satisfied" with flurbiprofen compared with placebo. 30, 36 There were no significant differences between flurbiprofen spray and lozenges in terms of GLOBAL 25 or SATIS.
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Flurbiprofen was also associated with benefit over placebo in studies using an overall treatment rating scale, 22, 31, 32 and in a paper from Russo et al 38 patients reported feeling significantly less distracted, less frustrated, and happier after taking flurbiprofen microgranules for 3 days compared with placebo (p<0.05).
Post-Operative Sore Throat (POST)
Two clinical studies investigating the effectiveness of flurbiprofen for the prevention of POST were eligible for inclusion in the review (Table 1) . 40 , 41 Uztüre et al 41 evaluated the efficacy of flurbiprofen lozenges for preventing POST, hoarseness and dysphagia symptoms in patients in whom a ProSeal laryngeal mask airway (LMA) was inserted during general anesthesia. A single flurbiprofen lozenge, given 45 min before induction of anesthesia, effectively reduced the severity of early POST (30 min postoperatively) and dysphagia compared with placebo (p<0.05 for both). Likewise, dysphagia was significantly lower in the flurbiprofen group compared with placebo at 4 h and hoarseness at 12 h postoperatively (p<0.05 for both). The incidence of POST symptoms was not significantly different between the flurbiprofen and placebo groups throughout the duration of the study. In the second study, Aydin et al 40 compared flurbiprofen lozenges with a sea salt and glycerine spray, a gargle used for the prevention of symptoms associated with stomatitis and gingivitis, and no treatment (control group) for the prevention of POST in 320 patients (n=80 for each treatment group) undergoing elective genitourinary surgery under general anesthesia. Treatment was again given 45 min prior to induction of anesthesia. There was a significantly lower incidence of POST in the flurbiprofen lozenge and Siccoral ® (Assos Pharmaceuticals, Istanbul, Turkey) spray groups at 0 and 1 h compared with those not treated (p<0.01 for all). There was a significantly lower incidence of POST in the Siccoral ® spray group compared with the flurbiprofen group at 0 h post-extubation (p=0.002), but the incidence of POST was similar between all groups at 6 and 24 h post-extubation (p=0.141 and p=0.426, respectively).
Although not eligible for full inclusion in this review due to the use of a lower dose of flurbiprofen (0.325 mg per spray; two sprays to each tonsillar fossa) the efficacy of flurbiprofen spray (three times a day for 7 days), has also been demonstrated for the management of post-tonsillectomy pain. 43 The severity of throat pain was lower in the flurbiprofen group (n=45) when compared with the placebo group (n=39), and this difference was statistically significant for all assessment days. Moreover, the flurbiprofen group required significantly less rescue analgesic than the placebo group during the study period on days 1, 3, 5, and 7.
Safety
Safety data from the reviewed studies are summarized in Table 7 . Overall, flurbiprofen 8.75 mg was well tolerated, regardless of formulation; in the majority of studies the incidence of treatment-emergent adverse events (TEAEs) was similar between the flurbiprofen and placebo treatment groups. 17, [28] [29] [30] [33] [34] [35] [36] [37] [38] The incidence of AEs was also similar between flurbiprofen and placebo in patients who were positive for strep A/C. 37 In three papers the incidence of TEAEs was significantly higher with flurbiprofen vs placebo; 22, 31, 32 taste perversion was the most commonly reported TEAE in these studies. Reports of taste perversion varied in their description by the patient; peppery taste, transient stinging or burning sensation, and unpleasant, bad or sour taste. 22, 31, 32 No relationship between taste perversion and changes to the oral mucosa was demonstrated on oral examination, 22, 31, 32 with the effect lasting only until dissolution of the lozenge was complete. 22 When taste perversion was removed from the analyses there was no significant difference in incidence of AEs between treatment groups. 22, 32 Most AEs thought to be "definitely", "probably" or "possibly" related to treatment were mild and transient, with no serious AEs reported for any of the formulations of flurbiprofen 8.75 mg. In addition to taste perversion, treatment-related AEs were most commonly associated with the digestive system (nausea, dyspepsia, diarrhea, abdominal pain/discomfort) or the nervous system (dry mouth, paresthesia, throat irritation). Discontinuations due to AEs were rare and generally resulted from AEs subsequently not considered to be of clinical relevance 31 or thought to be related to underlying medical conditions.- 36 Radkova et al 26 observed no significant differences in the incidence of TEAEs between the lozenge and the spray formulations.
Summary
Low dose (8.75 mg), locally administered flurbiprofen has been shown in the reviewed studies to provide effective relief of acute sore throat, including relief of throat pain and soreness, difficulty swallowing, sensation of swollen throat, and many other commonly reported qualities of sore throat. 17, 22, 25, 26, [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] This efficacy has been demonstrated across all the different locally administered formulations studied (lozenge, spray or microgranules), providing patients and HCPs with the option to select the most appropriate formulation for the individual without compromising on efficacy. Moreover, data have demonstrated that flurbiprofen is effective even in patients with more severe or painful symptoms, 29, 35 who are more likely to visit their doctor and more likely to take antibiotics. 4 Although these patients with more severe symptoms might be expected to be more resilient to the pharmacological effects of low dose (8.75 mg) flurbiprofen, studies demonstrated that the beneficial effects were actually similar or more pronounced in these patients compared with the overall study population. 29, 35 The reviewed studies confirm the fast onset of symptomatic relief with flurbiprofen, beginning as early as 1-2 min post-dose. 17, 25, 38 The demulcent activity of lozenges provides a rapid soothing effect ("active placebo") as soon as they are sucked and allows a high initial deposition of active ingredient in the mouth and throat. The spray formulation delivers a full dose immediately at the site of pain and inflammation, coating the posterior pharynx. 24 This early onset of relief was most apparent in studies that employed a short time interval between assessments (eg 2 min), and initial assessment within 1-2 min after flurbiprofen administration. 17, 25, 38 The data reviewed also demonstrate that "clinically meaningful" relief attributable to the anti-inflammatory effects of flurbiprofen occurs rapidly (from around 12 min post-dose) 17 and is sustained for up to 4-6 h (the last time point assessed after a single dose). 17, 30, [32] [33] [34] 37, 38 Sore throat lasts for around 3-7 days, 11 therefore, many patients will require repeated dosing to relieve ongoing symptoms. Seven of the nine studies included in this review reported data for single-and multiple-dose flurbiprofen, suggesting that flurbiprofen administered 3-6 hourly when required, up to five times a day for up to 7 days, continues to provide clinically relevant, long-lasting relief for those patients whose symptoms remain bothersome. [29] [30] [31] 34, [36] [37] [38] Patients entering these studies may have had a sore throat that started up to 7 days previously; therefore, the "first 24-h" period may actually have been up to the seventh day of these patients' symptoms. As acute sore throat is of limited duration, with over 80% improving within a week, 10 this may explain why the differences between flurbiprofen and placebo over subsequent days did not reach statistical significance in all of the studies. 30, 31, 38 Despite the fact that antibiotics are ineffective against viruses, 11, 14 and therefore inappropriate for up to 80% of pharyngitis cases, 10 antibiotic prescribing for this condition remains commonplace in primary care. 5 Current treatment guidelines advocate symptomatic relief of sore throat as firstline treatment; even in bacterial sore throat, antibiotics do not provide immediate or useful relief of symptoms, with half of patients still experiencing pain after 3 days. 11 Moreover, physicians face considerable challenges in the accurate diagnosis of bacterial sore throat, with misdiagnosis potentially leading to inappropriate antibiotic prescribing and antibiotic resistance. 5, 37 Shephard et al highlighted the unreliability of strep A diagnosis based on clinical findings, with an 86.9% false positive result for strep A based on diagnosis by clinical features alone. 37 Even using a rapid strep test, the study suggested that 23.9% of patients would have received antibiotics unnecessarily. 37 Given its proven efficacy at providing fast and long-lasting relief from sore throat, particularly in the first few days when symptoms are worst, 12, 13 flurbiprofen offers a useful first-line treatment option for symptomatic relief in patients with "uncomplicated" acute sore throat, thus helping to reduce unnecessary antibiotic prescribing. Studies confirm the efficacy of flurbiprofen in patients both with and without strep sore throat, 26, 28, 35, 37 although the analyses included in this review are limited by the relatively low incidence of strep A/C positive patients. As most strep sore throats will resolve naturally over time, flurbiprofen can be considered prior to a definitive diagnosis of strep A/C; with the single-dose effects lasting for 3-4 h in these patients, it is reassuring that more persistent, severe or worsening symptoms associated with strep throat are unlikely to be "masked", allowing patients to seek further advice and potentially antibiotics if required. 37 Even when the symptoms and course of sore throat suggest that antibiotics may be warranted, flurbiprofen can be safely combined with antibiotic therapy to effectively relieve pain and other symptoms that antibiotics will not immediately alleviate. 31 NSAIDs have been associated with gastrointestinal AEs, which have been shown to be dose related. 19 However, use of the lowest single dose of flurbiprofen proven to be effective for the relief of sore throat (8.75 mg) 22, 27 means that flurbiprofen was well-tolerated across the reviewed studies, with a predominantly mild and transient AE profile similar to placebo in the majority of studies. 17, [28] [29] [30] [33] [34] [35] [36] [37] [38] Taste perversion was more common with flurbiprofen lozenge than placebo in three studies; the high incidence of this AE can be attributed to the outdated Coding Symbols for a Thesaurus of Adverse Reaction Terms (COSTART) terminology used to classify the event in these older studies. 22, 31, 32 Taste perversion is considered to be related to patient acceptability rather than tolerability and lasts only until dissolution of the lozenge is complete. 22, 31, 32 However, as the reviewed studies observed that patients' ratings of satisfaction and overall treatment efficacy were significantly better with flurbiprofen treatment than with placebo, patient acceptability does not appear to be an issue. 22, 25, 26, [30] [31] [32] 34, 36, 38 The results of the two POST studies included in this review are consistent with the findings of previous studies confirming the efficacy of a preoperative, locally delivered NSAID for the prevention of POST. 45 A systematic review of clinical studies in adults undergoing elective surgery under general anesthesia found that the topical NSAID benzydamine significantly decreased the incidence of POST compared with nonanalgesic controls; however, POST severity was not significantly reduced in this comparison. 45 Benzydamine was also associated with a significant reduction in the incidence of POST when compared with lidocaine. 45 In conclusion, the studies included in this review confirm that single-and multiple-dose flurbiprofen 8.75 mg, locally administered in lozenge, spray or microgranule form, is a well-tolerated and effective first-line treatment option for the fast and long-lasting symptomatic relief of sore throat, including in patients with more severe symptoms, patients with confirmed strep A/C sore throat, and patients taking concomitant antibiotics. In addition, a single preoperative dose of flurbiprofen lozenge appears to be effective for preventing or reducing the severity of early POST in patients undergoing general anesthesia.
